Translational Development Acquisition Corp.
corporate_fare Company Profile
Translational Development Acquisition Corp. (NASDAQ:TDAC) is a publicly traded company in the Real Estate & Construction sector. Wiseek has independently scored 20 items for TDAC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-14, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 18 rated 8 or above. Recent SEC coverage for TDAC spans 10-Q, 425, 8-K, DEF 14A.
Recent high-impact activity:
- TDAC's Q2 10-Q Flags Ineffective Disclosure Controls and Going Concern Risk
- TDAC Locks In $50M PIPE from Naetas Holding, Complete with Warrants and Registration Rights
- TDAC Locks In $50M PIPE from Naetas Holding at $10/Share, Plus Warrants
- ProLogium Files F-4, Advancing TDAC De-SPAC Merger
- ProLogium Files F-4 Registration Statement for SPAC Merger with TDAC
Financial Snapshot
Short Interest & Short Volume
1.09 days to coverFINRA reported short interest of 18,793 shares in TDAC as of the September 15, 2026 settlement, a 0.4% increase from the prior period — about 1.1 days to cover at its recent average daily volume. On October 2, 2026, 5.8% of TDAC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.